Report of Foreign Issuer (6-k)
July 09 2020 - 7:32AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of the
Securities Exchange Act of 1934
For
the month of July 2020
Commission
File Number: 001-37643
KITOV
PHARMA LTD.
(Translation
of registrant’s name into English)
One
Azrieli Center, Round Tower, Tel Aviv 6701101, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On
July 8, 2020, Kitov Pharma Ltd. (the “Company” or the “Registrant”) issued a press release, “Kitov
Announces Initiation of Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients”, which is attached hereto as
Exhibit 99.1.
Exhibits
Incorporation
by Reference
This Form 6-K,
including all exhibits attached hereto, is hereby incorporated by reference into each of the Registrant’s Registration
Statements on Form F-3 filed with the SEC on December 12, 2016 (Registration file numbers 333-207117 and 333-211477),
the Registrant’s Registration Statement on Form
S-8 filed with the SEC on May 20, 2016 (Registration file number 333-211478), the Registrant’s Registration Statement
on Form S-8 filed
with the SEC on June 6, 2017 (Registration file number 333-218538), the Registrant’s Registration Statement on Form
F-3, as amended, originally filed with the SEC on July 16, 2018 (Registration file number 333-226195), the Registrant’s
Registration Statement on Form
S-8 filed with the SEC on March 28, 2019 (Registration file number 333-230584), the Registrant’s Registration Statement
on Form F-3 filed
with the SEC on September 16, 2019 (Registration file number 333-233795), the Registrant’s Registration Statement on Form
F-3 filed with the SEC on December 2, 2019 (Registration file number 333-235327), the Registrant’s Registration
Statement on Form
F-3 filed with the SEC on May 13, 2020 (Registration file number 333- 238229), and the Registrant’s Registration
Statement on Form
S-8 filed with the SEC on May 18, 2020 (Registration file number 333-238481), to be a part thereof from the date
on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
July
9, 2020
|
KITOV
PHARMA LTD.
|
|
|
|
|
By:
|
/s/
Isaac Israel
|
|
|
Isaac
Israel
|
|
|
Chief
Executive Officer
|
2
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Sep 2023 to Sep 2024